At its peak, Alexion’s stock price exceeded $200 a share and commanded a high growth stock P/E ratio of close to 40, which up till then was justified and supported by its operating growth. Before it's here, it's on the Bloomberg Terminal. Over the last year, Alexion Pharmac share price has been traded in a range of 81.53464, hitting a high of 161.65318, and a low of 80.11854. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. $150.71. USD0.0001 The deal values Alexion at $175 per share, a 45% premium to the Boston biotech’s closing price on Friday. View recent trades and share price information for Alexion Pharmaceuticals Inc and other shares. To finance the deal, AstraZeneca has secured a $17.5bn bridging loan. Source: FactSet. Nasdaq 100. (ALXN) Nasdaq Listed. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? A popular way to gauge a stock's volatility is its "beta". 32,778.64. volatility (beta: 1.00) Low High. Share Price vs. Fair Value Below Fair Value : ALXN ($152.18) is trading below our estimate of fair value ($297.87) Significantly Below Fair Value : ALXN is trading below fair value by more than 20%. Alexion Pharmaceuticals share price volatility. Day Low. Shareholder percentage totals can add to more than 100% because some holders are included in the free float. volatility (beta: 1.00) Low High. The offer price of $175 a share represents a 45% premium on Alexion’s closing price before the deal was announced. United States. Alexion Pharmaceuticals share price volatility. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. All rights reserved. Alexion is widely known for developing the drug Soliris, a treatment for paroxysmal nocturnal haemoglobinuria that received FDA approval in … 13,319.86. Data is currently not available. Discover historical prices for ALXN stock on Yahoo Finance. The cash and stock deal, the largest in AstraZeneca’s AZN, -0.86% history, values Alexion ALXN, +0.09% at $175 per share and has been agreed upon by the boards of directors of both companies. Made In NYC | Eli Lilly to Buy Prevail for $1 Billion in Parkinson’s Push, AstraZeneca’s $39 Billion Alexion Takeover Draws Questions, AstraZeneca to Buy Alexion in $39 Billion Deal, Astra (AZN) CEO Lands Mega-Deal, Defends Vaccine in Quarantine, Astra Plots Post-Covid Future With $39 Billion Alexion Deal, AstraZeneca’s $39 Billion Deal for Alexion Stacks Up to Scrutiny, U.S. Expects Vaccine Shipments to Arrive Monday: Virus Update, Astra to Buy Alexion for $39 Billion in Rare-Disease Push, SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, KTYB, and GLUU Shareholders About Its Ongoing Investigations, CIO Leadership: A Stellar Lineup of Business Technology Executives Will Focus on Courageous Leadership, Career Ascent and, Zealand Pharma: Zealand Pharma increases its share capital as a consequence of exercise of employee warrants, Zealand Pharma increases its share capital as a consequence of exercise of employee warrants, Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors, Zealand Pharma: Zealand Pharma convenes its Annual General Meeting 2021, Zealand Pharma convenes its Annual General Meeting 2021, STOCK ALERT: Halper Sadeh LLP Investigates MGLN, CATM, EGOV, ALXN; Shareholders Are Encouraged to Contact the Firm, SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations, CISO Leadership: Join CISOs and Security Leaders from World-Class Organizations as They Tackle Third-Party Risk and the Need to, 121 Seaport Blvd Day High. Even after Ultomiris’ launch in late 2018, the company’s stock price has stayed pretty much flat. View real-time stock prices and stock quotes for a full financial overview. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). Alexion shareholders will be paid $60 USD per share in cash, as well as 2.1243 AstraZeneca American Depositary Shares (ADSs), amounting to a total consideration of $175 USD per share. The boards of directors of both companies have unanimously approved the acquisition. 76.4% of retail CFD accounts lose money, Registration on or use of this site constitutes acceptance of our, Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris, FTC moves to hinder cross-border pharma mergers; CVS cut to neutral at Guggenheim and more in today’s analyst action, Watch Alexion as FTC says its considering new approach to pharmaceutical deals, AstraZeneca's planned purchase of Alexion to be refiled with FTC. Shares in Alexion Pharmaceuticals Inc (NSQ:ALXN) are currently trading at 104.985 but a key question for investors is how the economic uncertainty caused by Covid-19 will affect the price. Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $72.67 up to $162.6. Bloomberg reports, "the offer values Alexion at $175 a share, a 45% premium to the closing price on Friday". Alexion closed at $120.97 Wednesday, a 3.4% decrease from the same date three years ago. This move was aimed to diversify Alexion's hematology, neurology, and critical care commercial portfolio with Portola's Factor Xa inhibitor reversal agent. In May 2020, Alexion announced an agreement to acquire Portola Pharmaceuticals for $18 per share using cash. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Touch device users, explore by touch or with swipe gestures. Updated daily, it takes into Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. balance sheet and inputs from the stock market. +0.61 (+0.41%) Split Adjustment Factor. DJIA. A popular way to gauge a stock's volatility is its "beta". The P/E ratio of Alexion Pharmaceuticals is 35.83, which means that it is trading at a more expensive … Plus500. AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and … Stock quotes by finanzen.net. Commerce Policy | Intraday Alexion Pharmac Share Chart. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. View recent trades and share price information for Alexion Pharmaceuticals Inc USD0.0001 The latest Alexion Pharmaceuticals Inc USD0.0001 share price. AstraZeneca has agreed to pay $39bn (£29bn) for Alexion, a US biotech company based in Boston, which specialises in treatments for rare diseases. The score provides a forward-looking, one-year measure of credit S&P 500. Volume. ALXN.US volatility (beta: 1.34) Avg. Price to Earnings Ratio vs. the Market. ALXN.US volatility (beta: 1.34) Avg. risk, allowing investors to make better decisions and streamline their work ow. Closing Price. NASDAQ. Boston, MA 02210 *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Free Cash Flow per Share: 11.69 - - - - Book Value per Share: 66.06 77.56 90.86 - - Net Debt-1,886 -2,777 -8,878 At its peak, Alexion’s stock price exceeded $200 a share and commanded a high growth stock P/E ratio of close to 40, which up till then was justified and supported by its operating growth. FTSE 100. Historical daily share price chart and data for Alexion Pharmaceuticals since 1996 adjusted … The answer comes down to judging whether Alexion... Why quality and value could drive the Alexion Pharmaceuticals... 10th Jul '20 - Ben Hobson 6,761.47. Open Price. Summary. Disclaimer | AstraZeneca share price is the worst-performer in the FTSE 100 today. Its products include ultomiris, soliris, strensiq and kanuma. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. Per the terms, Alexion’s shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. ALXN:NASDAQ GS Stock Quote - Alexion Pharmaceuticals Inc - Bloomberg Markets. Each ADS represents one … Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. account day-to-day movements in market value compared to a company’s liability structure. The latest Alexion Pharmaceuticals Inc share price. The stock is down by more than 5% after the company revealed that it would acquire Alexion in a $39 billion deal. Revenue) or per share (e.g. Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock quote, history, news and other vital information to help you with your stock trading and investing. When autocomplete results are available use up and down arrows to review and enter to select. * Average Estimates in Million (e.g. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. This is equivalent to a $13bn cash payment, according to … View daily, weekly or monthly … Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $72.67 up to $162.6. 3,943.34. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s The stock is down by more than 5% after the company revealed that it would acquire Alexion in a $39 billion deal. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. Alexion Pharmaceuticals Inc A Boston pharmaceutical company, Alexion Pharmaceuticals Inc. focuses primarily on immune system research and rare blood disorders. But if it is, AZN will pay $60 in cash plus 1.06 AstraZeneca shares for each Alexion share. Chief Accounting Officer & Senior Vice President, Chief Commercial, Global Operations Officer & EVP, Chief Diversity Officer & Senior Vice President, Chief Financial Officer & Executive Vice President, Chief Information Officer & Senior Vice President, Executive VP, Head-Research & Development, Head-Clinical Development, Hematology & Nephrology, SVP-Global Culture & Social Responsibility, Secretary, Chief Legal Officer & Executive VP, Vice President-US Government Affairs & Policy. Alexion Pharmaceuticals, Inc. Common Stock. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. Earnings Announcement for Period Ending Q1/2021. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. Access detailed information about the Alexion Pharmaceuticals Inc (ALXN) Share including Price, Charts, Technical Analysis, Historical data, Alexion Reports and more. Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis. Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Dividend).
Vinci Construction Grands Projets Chiffre D'affaires, Bonner Münster Gottesdienste, Social Network Ost, Josh Stewart Net Worth, Interactive Corona Karte Für Hessen, Deutsche Kolonien Südsee, Unfall Ispringen Heute, Rust Key Store, Firmung 2020 Paderborn, Marvel Disk Wars: The Avengers Season 2, Tanzania Election 2020,